Lassa virus envelope glycoprotein GP mutant and application thereof in preparation of Lassa vaccine

By designing the glycosylation site mutation of LASV GP, a glycosylation site mutant of pre-fusion conformation GP was formed, which solved the problem of poor induction of neutralizing antibodies in the existing LASV vaccine and achieved efficient neutralizing antibodies. and Th1 type cellular immune response significantly improve the protective effect of the vaccine.

CN118909054APending Publication Date: 2024-11-08FOURTH MILITARY MEDICAL UNIVERSITY
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202411271059.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-11
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The existing LASV vaccines are not effective in inducing neutralizing antibodies, cannot effectively block LASV infection, and there are problems of virulence rebirth and low replication rates.

Method used

Glycosylation site mutation was performed based on LASV GP, and glycosylation site mutants were designed for pre-fusion conformation GP. By introducing disulfide bonds and proline, mutations of multiple glycosylation sites were performed. , insert the eukaryotic expression vector pVAX1 to form a variety of plasmid antigens, inducing mice to produce neutralizing antibodies and Th1-type cellular immune responses.

Benefits of technology

The successful induction of mice to produce neutralizing antibodies and Th1-type cellular immune responses significantly improved the neutralization activity against LASV pseudovirus and provided an efficient antigen design strategy for LASV vaccines.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118909054A_ABST
    Figure CN118909054A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biology, in particular to a Lassa virus envelope glycoprotein GP mutant and application thereof in preparation of Lassa vaccines. The Lassa virus envelope glycoprotein GP mutant is obtained by performing amino acid mutation modification on a wild type LASV GP full-length sequence as shown in SEQ ID NO.1, the coding gene sequence of the obtained Lassa virus envelope glycoprotein GP mutant is as shown in SEQ ID NO.11 or SEQ ID NO.12, and the Lassa virus envelope glycoprotein GP mutant is respectively inserted into eukaryotic expression vectors to obtain two plasmid antigens PF-ND4 and PF-ND4-R4; according to the invention, formation of a mouse drainage lymph node hair growing center, T cell immune response and serum neutralizing antibody activity are detected, and results show that humoral immune response and neutralizing antibody can be induced by a design strategy of mutation of four glycosylation sites on the basis of conformation before fusion. The invention provides a new strategy for preventing and treating lasa fever.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a Lassa virus envelope glycoprotein GP mutant and an application thereof in the preparation of a Lassa vaccine. Background Art

[0002] Lassa fever (LF) is an acute viral hemorrhagic fever caused by Lassa virus (LASV) infection. The main clinical manifestations are fever, chills, pharyngitis, pain behind the sternum and proteinuria. Multiple systemic lesions may occur, and the mortality rate can be as high as 50%. Currently, there is no approved LF vaccine, so there is an urgent need to develop a vaccine against LASV.

[0003] Under natural infection conditions, after humans and non-human primates are infected with LASV, no matter whether they die or recover, they cannot induce effective antibody responses. However, in the immune response to acute viral infection, neutralizing antibodies play a very important role in neutralizing the virus and blocking viral infection. Existing studies have shown that plasma from recovered patients containing neutralizing antibodies can produce effective animal protection effects. This suggests that inducing an effective neutralizing antibody response can block LASV infection, thereby achieving the purpose of preventing infection. In addition, LASV has a high degree of genetic diversity. Four lineages (I-IV) have been confirmed, and there are three lineages (V-VII) that are not widely recognized. Therefore, inducing the production of a broad spectrum of highly active neutralizing antibodies is the main direction of research on efficient LASV vaccines.

[0004] At present, LASV vaccine research mainly includes live attenuated vaccines, inactivated vaccines, recombinant viral vector vaccines, subunit vaccines, viral VLP vaccines and nucleic acid vaccines, all of which use LASV GP as antigen. LASV live attenuated vaccines can protect non-human primates from the attack of lethal LASV, but the safety issues such as virulence reversion that cannot be ignored in attenuated vaccines have hindered the LASV live attenuated vaccines from entering the clinic. At the same time, after guinea pigs are immunized with LASV inactivated vaccines, certain specific antibodies can be induced, but when animals are challenged with a lethal dose of LASV, although the onset of the disease is delayed, all animals die, so inactivated vaccines cannot induce complete protection against LASV. There are currently many studies on LASV vaccines based on viral vectors. For example, yellow fever virus vectors expressing LASV GP can induce specific antibodies and low levels of neutralizing antibodies, but the replication rate of the chimeric virus is very low and it cannot be stably propagated in cells. The recombinant adenovirus vector vaccine expressing LASV GP can induce the production of specific antibodies in mice after immunization, and has a certain animal protection effect in the pseudovirus challenge experiment, but no neutralizing antibody response was detected.

[0005] In summary, the LASV vaccines currently under development that use LASV GP as an antigen have failed to induce the production of high levels of neutralizing antibodies. Therefore, it is necessary to modify LASV GP to obtain LASV vaccine antigens that can induce the body to produce high levels of neutralizing antibodies. Summary of the invention

[0006] To solve the above problems, the present invention provides a LASV vaccine antigen design strategy for mutating glycosylation sites based on the pre-fusion conformation GP. After immunizing mice with LASV vaccine antigens designed using this strategy, neutralizing antibodies that neutralize LASV pseudovirus can be induced, and the formation of germinal centers in the draining lymph nodes of mice can be promoted, and Th1 type cellular immune responses can be efficiently induced. That is, the LASV vaccine design strategy for mutating glycosylation sites based on the pre-fusion conformation GP can induce humoral immune responses and produce neutralizing antibodies.

[0007] LASV GP is a major antigen that induces neutralizing antibodies. According to the LASV GP gene sequence, the present invention first introduces a disulfide bond (R207C, G360C) and a proline (E329P) to form a pre-fusion conformation (PF), and on this basis, two glycosylation sites (N390D, N395D) are mutated (PF-ND2), four glycosylation sites (N390D, N395D, N224D, N373D) are mutated (PF-ND4), and four glycosylation sites and enzyme cleavage sites are mutated together (N390D, N395D, N224D, N373D and RRRR, PF-ND4-R4), and the eukaryotic expression vector pVAX1 is inserted into them respectively to obtain four plasmid antigens PF, PF-ND2, PF-ND4 and PF-ND4-R4, and protein immunoblotting (WB) is used to identify that the above plasmids are correctly expressed.

[0008] The present invention further detected the formation of germinal centers in the draining lymph nodes of mice, T cell immune response and serum neutralizing antibody activity after mice were immunized with the above four plasmid antigens. The results showed that the cellular immune response after plasmid PF-ND4 immunization was Th1 type, and the neutralizing activity of mouse serum against LASV pseudovirus pVSV-LASV-Nluc was higher than that of other groups, indicating that the design strategy of mutating four glycosylation sites based on the pre-fusion conformation can induce humoral immune response and neutralizing antibodies.

[0009] Therefore, the first object of the present invention is to provide a LASV GP protein mutant, wherein the LASV GP protein mutant is obtained by performing amino acid mutation modification on the wild-type LASV GP full-length sequence as shown in SEQ ID NO.1, and the LASV GP protein mutant is obtained by any one of the following two methods:

[0010] (1) The arginine R at position 207 of SEQ ID NO.1 was mutated to cysteine ​​C, the glutamic acid E at position 329 was mutated to proline P, the glycine G at position 360 was mutated to cysteine ​​C, and the asparagine N at positions 390, 395, 224 and 373 were mutated to aspartic acid D;

[0011] (2) The arginine R at position 207 of SEQ ID NO.1 is mutated to cysteine ​​C, the glutamic acid E at position 329 is mutated to proline P, the glycine G at position 360 is mutated to cysteine ​​C, the asparagine N at positions 390, 395, 224 and 373 are mutated to aspartic acid D, and the leucine L at positions 258 and 259 are mutated to arginine R.

[0012] Furthermore, the coding gene sequence of the LASV GP protein mutant obtained by the method described in (1) is shown as SEQ ID NO.11.

[0013] Furthermore, the coding gene sequence of the LASV GP protein mutant obtained by the method described in (2) is shown in SEQ ID NO.12.

[0014] The second object of the present invention is to provide a biomaterial, which is at least one of the following (1)-(4):

[0015] (1) A nucleic acid molecule encoding the LASV GP protein mutant according to claim 1;

[0016] (2) a recombinant vector containing the nucleic acid molecule described in (1);

[0017] (3) a recombinant microorganism containing the nucleic acid molecule described in (1) or a recombinant microorganism containing the recombinant vector described in (2);

[0018] (4) A recombinant cell line containing the nucleic acid molecule described in (1) or a recombinant cell line containing the recombinant vector described in (2).

[0019] The third object of the present invention is to provide the use of the LASV GP protein mutant or the biological material in any one of the following (1)-(3):

[0020] (1) Preparing anti-LASV products;

[0021] (2) preparing products for the prevention and / or treatment of LASV infection;

[0022] (3) Preparation of products for preventing and / or treating diseases caused by LASV.

[0023] The fourth object of the present invention is to provide a neutralizing antibody-inducing LASV vaccine, the active ingredient of which is the LASV GP protein mutant or the biological material.

[0024] Furthermore, the vaccine is a DNA vaccine, an mRNA vaccine, a recombinant protein subunit vaccine, a recombinant protein subunit vaccine displayed by nanoparticles, or a recombinant vector vaccine.

[0025] Furthermore, the vaccine is in the form of an aqueous solution or a lyophilized preparation.

[0026] A fifth object of the present invention is to provide the use of the vaccine in any of the following (1)-(3):

[0027] (1) Preparing anti-LASV products;

[0028] (2) preparing products for the prevention and / or treatment of LASV infection;

[0029] (3) Preparation of products for preventing and / or treating diseases caused by LASV.

[0030] Compared with the prior art, the present invention has the following beneficial effects:

[0031] 1. The antigen in the present invention is plasmid DNA, which can directly express the original conformation viral antigen, has both endogenous and exogenous antigen presentation pathways, is less affected by the environment, has low production costs, and has a relatively simple production process. It can be quickly designed and put into production, which is convenient for clinical and laboratory applications.

[0032] 2. The present invention detected the formation of germinal centers in mouse draining lymph nodes, T cell immune response and serum neutralizing antibody activity. The results showed that the design strategy of mutating four glycosylation sites based on the pre-fusion conformation can induce humoral immune response and neutralizing antibodies. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 The PCR electrophoresis results of R207C seg1 and R207C seg2, and R207C-E329P seg1 and R207C-E329P seg2 are shown.

[0034] Figure 2 The electrophoresis results of the splicing products of R207C seg1 and R207C seg2, and the splicing products of R207C-E329P seg1 and R207C-E329Pseg2 are shown.

[0035] Figure 3 This is the electrophoresis result of the PCR products of pCAGGS-LASV GP / R207C and pCAGGS-LASV GP / R207C-E329P plasmids.

[0036] Figure 4 This is the electrophoresis result of the PCR product of pCAGGS-LASV GP / R207C-E329P-G360C plasmid.

[0037] Figure 5 This is the electrophoresis result of the splicing products of 207C-E329P-G360C seg1 and R207C-E329P-G360C seg2.

[0038] Figure 6 This is the electrophoresis result of the PCR product of pCAGGS-PF plasmid.

[0039] Figure 7 This is the electrophoresis result of pUC-PF-ND2 plasmid PCR product.

[0040] Figure 8 This is the electrophoresis result of the PCR product of pCAGGS-PF-ND2 plasmid.

[0041] Fig. 9 This is the electrophoresis result of the double enzyme digestion products of pUC-PF-ND4 and pUC-PF-ND4-R4 plasmids.

[0042] Fig.10 This is the electrophoresis result of double enzyme digestion products of pCAGGS-PF-ND2, pCAGGS-PF-ND4, and pCAGGS-PF-ND4-R4 plasmids.

[0043] Fig.11 The electrophoresis results of LASV GP-PF and LASV GP-PF-ND2 are shown.

[0044] Fig.12 The electrophoresis results of LASV GP-PF-ND4 and LASV GP-PF-ND4-R4 are shown.

[0045] Fig.13 This is the electrophoresis result of PCR products of pVAX1-PF, pVAX1-PF-ND, pVAX1-PF-ND4 and pVAX1-PF-ND4-R4 plasmids.

[0046] Fig.14 Western Blot results of pVAX1, pVAX1-GP, pVAX1-PF, pVAX1-PF-ND2, pVAX1-PF-ND4 and pVAX1-PF-ND4-R4 plasmids.

[0047] Fig.15 The levels of IFN-γ secreted by spleen cells of mice in each group.

[0048] Fig.16 The levels of cytokine IL-2 secreted by spleen cells of mice in each group.

[0049] Fig.17 The levels of IL-4 secretion by spleen cells of mice in each group.

[0050] Fig.18 The levels of IL-10 secreted by spleen cells of mice in each group.

[0051] Fig.19 is the neutralizing antibody activity of the mouse serum in each group. DETAILED DESCRIPTION

[0052] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.

[0053] Experimental Materials

[0054] The pVSV-dG.G-Nluc virus was constructed and preserved by our laboratory. The construction method is as follows:

[0055] After pVSVΔG-GFP was digested with Xho I, pVSVΔG was recovered by electrophoresis and gel, and the Nluc sequence (SEQ ID NO.15) was cloned into the plasmid pVSVΔG through the Xho I restriction site to construct the plasmid pVSVΔG-Nluc, which was co-transfected with the VSV auxiliary plasmids pBS-N, pBS-P, pBS-G, and pBS-L into BHK-21 cells transiently expressing T7 polymerase to package the pseudovirus pVSV-dG.G-Nluc. pVSVΔG-GFP was purchased from Nanjing GenScript Co., Ltd.

[0056] The pCAGGS-X-myc vector was obtained by inserting the myc sequence (as shown in SEQ ID NO. 16) into the KpnI and XhoI sites of the pCAGGS vector (kindly donated by the Chinese Academy of Agricultural Sciences).

[0057] 4% paraformaldehyde; TritonX-100; BSA were purchased from YEASEN; anti-Myc antibody was purchased from Abbkine; HRP-Goat-Anti-mouse IgG was purchased from Sangon Biotechnology Co., Ltd.; anti-CD4-FITC, anti-CD45R-APC / Cy7, anti-PD1-PE, anti-CXCR5-BV421, anti-CD3-PE / Cy7, anti-CD4-FITC and anti-CD8-APC / Fire750 antibodies were purchased from eBioscience; SPARK multifunctional microplate reader was purchased from company.

[0058] 1. Plasmid construction based on pCAGGS vector

[0059] 1. Construction of mutant pCAGGS-LASV GP / R207C plasmid

[0060] The LASV GP used in this experiment was the viral gene sequence of the standard strain Josiah of LASV of line IV (NC_004296.1), which was synthesized after codon optimization by Beijing Sino Biological Technology Co., Ltd. and inserted between the EcoR I and XhoI sites of the pCMV3 vector (product name Lassa virus LASV (strain Josiah) glycoprotein ORF mammalian expression plasmid (Codon Optimized, catalog number VG40079-UT) to obtain the plasmid pCMV3-LASV GP. The nucleotide sequence of LASV GP in the plasmid pCMV3-LASV GP is shown in SEQ ID NO.1; then point mutations were made at the amino acid sites 207, 329 and 360, respectively, as follows:

[0061] pCMV3-LASV GP was used as a template to design corresponding mutation primers, including upstream primer LASV GP-F-infu (the gene sequence is shown in SEQ ID NO.2), downstream primer LASV GP-R-infu (the gene sequence is shown in SEQ ID NO.3), downstream primer LASV-GP-R207C-Seg1-R (the gene sequence is shown in SEQ ID NO.4), and upstream primer LASV-GP-R207C-Seg2-F (the gene sequence is shown in SEQ ID NO.5);

[0062] SEQ ID NO.1:

[0063] ATGGGACAAATTGTGACCTTCTTCCAGGAGGTGCCTCATGTGATTGAGGAGGTGATGAACATTGTGCTGATTGCCCTGTCTGTGCTGGCTGTGCTGAAAGGACTCTACAACTTTGCCACTTGTGGACTGGTGGGACTGGTGACCTTCCTGCTGCTGTGTGGCAGGTCCTGTACCACCTCCCTCTACAAGGGAGTCTATGAACTCCAAACCTTGGAACTGAATATGGAGACCCTGAATATGACAATGCCACTGTCCTGTACCAAGAACAACAGCCACCACTACATAATGGTGGGCAATGAGACAGGATTGGAACTGACCCTGACCAACACCAGCATCATCAACCACAAGTTCTGTAACCTGTCTGATGCCCACAAGAAGAACCTCTATGACCATGCCCTGATGAGTATCATCAGCACCTTCCACCTGAGCATCCCAAACTTCAACCAATATGAGGCTATGAGTTGTGACTTCAATGGAGGCAAGATTTCTGTCCAATACAACCTGAGCCACTCCTATGCTGGAGATGCTGCCAACCACTGTGGCACAGTGGCTAATGGAGTGCTCCAAACCTTTATGAGGATGGCTTGGGGAGGCTCCTACATTGCCCTGGACTCTGGCAGGGGCAACTGGGACTGTATAATGACCTCCTACCAATACCTGATTATCCAGAACACCACCTGGGAGGACCACTGTCAGTTCAGCAGACCAAGCCCAATTGGCTACCTGGGACTGCTGAGCCAGAGGACCAGGGACATCTACATCAGCAGGAGACTGCTGGGCACCTTCACCTGGACCCTGTCTGACTCTGAGGGCAAGGACACACCTGGAGGCTACTGTCTGACCAGGTGGATGCTGATTGAGGCTGAACTGAAATGTTTTGGCAACACAGCAGTGGCTAAGTGTAATGAGAAACATGATGAGGAGTTCTGTGATATGCTGAGACTGTTTGACTTCAACAAGCAGGCTATCCAGAGACTGAAAGCAGAGGCTCAAATGAGTATCCAACTTATCAACAAGGCTGTGAATGCCCTGATAAATGACCAACTTATAATGAAGAACCACCTGAGGGACATAATGGGCATCCCATACTGTAACTACAGCAAATACTGGTATCTGAACCACACCACCACAGGCAGGACCTCCCTGCCAAAGTGTTGGCTGGTGAGCAATGGCTCCTACCTGAATGAGACCCACTTCTCTGATGACATTGAACAACAGGCTGACAATATGATTACAGAGATGCTCCAAAAGGAATATATGGAGAGACAGGGCAAGACACCACTGGGACTGGTGGACCTGTTTGTGTTCAGCACCTCCTTCTACCTGATTAGCATCTTCCTGCACCTGGTGAAGATTCCAACCCACAGACACATTGTGGGCAAGTCCTGTCCAAAGCCACACAGACTGAACCACATGGGCATCTGTTCCTGTGGACTCTACAAGCAACCTGGAGTGCCTGTGAAGTGGAAGAGGTAA;

[0064] SEQ ID NO.2:

[0065] CATTTTGGCAAAGAATTCgccaccATGGGACAAATTGTGACCTTCTTCCA GGAG;

[0066] SEQ ID NO.3:

[0067] GAGCCTCCACCCCCGGTACCCCTCTTCCACTTCACAGGCACTCCAGG;

[0068] SEQ ID NO.4:

[0069] GCCAGAGTCCAGGGCAATGTAGGAGCCTC;

[0070] SEQ ID NO.5:

[0071] CTCCTACATTGCCCTGGACTCTGGCTGCGGCAACTGGGACTGTATAAT GACCTC。

[0072] R207C seg1 and R207C seg2 were amplified by PCR using Q5 DNA polymerase. The PCR reaction system was as follows: template pCMV3-LASV GP 1 μL, upstream primer LASV GP-F-infu (gene sequence as shown in SEQ ID NO.2) 0.5 μL, downstream primer LASV-GP-R207C-Seg1-R 0.5 μL (gene sequence as shown in SEQ ID NO.4), Q5 enzyme 0.25 μL, dNTP 0.5 μL, 5× buffer 5 μL, ddH2O 17.75 μL. This reaction system amplified R207C seg1; using the same template, upstream primer LASV-GP-R207C-Seg2-F (gene sequence as shown in SEQ ID NO.5), and downstream primer LASV GP-R-infu (gene sequence as shown in SEQ ID NO.3) amplified R207C seg2.

[0073] The reaction conditions were: 98°C for 30 s, 98°C for 15 s, 55°C for 10 s, 72°C for 90 s, 30 cycles, 72°C for 5 min, 10°C forever; the PCR product was verified by 1% agarose gel electrophoresis (TAE electrophoresis fluid). Figure 1 The PCR result of R207C seg1 and R207C seg2 was shown in Figure 2. R207C seg1 and R207C seg2 were spliced ​​by PCR. The PCR product was verified by 1% agarose gel electrophoresis (TAE electrophoresis solution). Figure 2 A band of the expected size can be observed in the gel; the gel is cut and the target band is recovered using a gel recovery kit.

[0074] pCAGGS-X-myc was double-digested with EcoR I and Kpn I. The double-digestion system was as follows: pCAGGS-X-myc 1 μg, EcoR I 1 μL, Kpn I 1 μL, 10×Buffer 3 μL, and the remaining amount of ddH2O was added to make the total volume 30 μL; the digestion was carried out in a 37°C water bath for 2 h. After the digestion product was verified to be correct by 1% agarose gel electrophoresis, the gel was cut and the target band was recovered using a gel recovery kit; the PCR product obtained by the above amplification was ligated with the pCAGGS-X-myc vector after double digestion to construct the LASV GP single mutant pCAGGS-LASV GP / R207C. The ligation reaction system was pCAGGS-X-myc vector 50 ng, R207C seg1 36 ng, R207Cseg2 32 ng, 5×In-Fusion Enzyme Premix 0.8 μL, add the remaining amount of ddH2O to make the total volume 30 μL; the connection condition is 50℃ water bath for 40 min.

[0075] Take 5 μL of the ligation product and add it to the DH5α competent bacteria, mix gently, place on ice for 30 minutes, heat shock at 42°C for 90 seconds, place on ice for 90 seconds, add 1 mL of LB culture medium without antibiotics, mix gently, place on a 37°C shaker for 1 hour, centrifuge at 5000g for 3 minutes, take 200 μL of the supernatant to resuspend the precipitated bacteria, evenly spread on the ampicillin-resistant LB solid culture plate, and invert the plate in a 37°C incubator for overnight culture. Pick a single clone colony from the plate, inoculate it in 5 mL of 2×YT culture medium containing ampicillin resistance, shake the bacteria in a 37°C constant temperature shaker overnight, extract the plasmid from the bacterial solution for PCR identification, and the pCAGGS-LASV GP / R207C plasmid is obtained correctly.

[0076] Recombinant plasmid pCAGGS-LASV GP / R207C 1ng, upstream primer LASV GP-F-infu (gene sequence as shown in SEQ ID NO.2) 0.5μL, downstream primer LASV GP-R-infu (gene sequence as shown in SEQ ID NO.3), Q5 enzyme 0.25μL, dNTP 0.5μL, 5× buffer 5μL, ddH2O 17.75μL, amplify LASV GP / R207C. PCR product was verified by 1% agarose gel electrophoresis. Figure 3 This is the PCR identification result of the pCAGGS-LASV GP / R207C plasmid. A band consistent with the expected size can be observed. The corresponding recombinant plasmid was sent to Sangon Biotech for sequencing verification, and the pCAGGS-LASVGP / R207C plasmid was obtained.

[0077] 2. Construction of pCAGGS-LASV GP / R207C-E329P plasmid

[0078] Using the successfully constructed pCAGGS-LASV GP / R207C plasmid as a template, relevant upstream and downstream primers were designed, including a LASV GP-E329P-seg1-R primer having a gene sequence as shown in SEQ ID NO.6 and a LASV GP-E329P-seg2-F primer having a gene sequence as shown in SEQ ID NO.7; then, PCR amplification of R207C-E329P seg1 and R207C-E329Pseg2 was performed using LASV GP-F-infu, LASV GP-E329P-seg1-R; LASV GP-E329P-seg2-F, LASV GP-R-infu as primers, respectively. The specific PCR reaction system and reaction conditions refer to the above method.

[0079] The PCR products were verified by 1% agarose gel electrophoresis ( Figure 1As shown), the gel was cut and the target bands R207C-E329P seg1 and R207C-E329P seg2 were recovered; R207C seg1 and R207C seg2 were then spliced ​​by PCR, and the PCR products were verified by 1% agarose gel electrophoresis (TAE electrophoresis solution). Figure 2 A band of the expected size can be observed in the gel; the gel was cut and the target band was recovered using a gel recovery kit; the recovered target band was connected to the pCAGGS-X-myc vector after double digestion with EcoR I and Kpn I to construct the double mutant pCAGGS-LASV GP / R207C-E329P. The ligation reaction and subsequent transformation experiments were as described above. The plasmid pCAGGS-LASV GP / R207C-E329P was used as a template, and LASV GP-F-infu (the gene sequence is shown in SEQ ID NO.2) and LASV GP-R-infu (the gene sequence is shown in SEQ ID NO.3) were used as upstream and downstream primers for PCR identification, as shown in FIG. Figure 3 As shown, a band consistent with the expected size can be observed, which preliminarily indicates that the plasmid was successfully constructed. The plasmid was sent to Shenggong Biotechnology Co., Ltd. for sequencing, which further indicated that the plasmid was successfully constructed and was stored for future use.

[0080] SEQ ID NO.6:

[0081] TGCTTTCAGTCTCTGGATAGCCTGCTTGTTG;

[0082] SEQ ID NO.7:

[0083] GCAGGCTATCCAGAGACTGAAAGCACCGGCTCAAATGAGTATCCAACTTATCAAC.

[0084] 3. Construction of LASV pre-fusion conformation GP plasmid pCAGGS-PF / R207C-E329P-G360C

[0085] Using the successfully constructed pCAGGS-LASV GP / R207C-E329P plasmid as a template, relevant upstream and downstream primers were designed, including a LASV GP-G360C-seg1-R primer having a gene sequence as shown in SEQ ID NO.8 and a LASV GP-G360C-seg2-F primer having a gene sequence as shown in SEQ ID NO.9; then, PCR amplification of R207C / E329P / G360Cseg1 and R207C / E329P / G360Cseg2 was performed using LASV GP-F-infu, LASV GP-G360C-seg1-R; LASV GP-G360C-seg2-F, LASV GP-R-infu as primers, respectively. The specific PCR reaction system and reaction conditions refer to the above method.

[0086] The PCR products were verified by 1% agarose gel electrophoresis ( Figure 4 The gel was cut and the target bands R207C-E329P-G360C seg1 and R207C-E329P-G360C seg2 were recovered. The two fragments were then spliced ​​by PCR. The PCR products were verified by 1% agarose gel electrophoresis (TAE electrophoresis solution). Figure 5 The bands with the expected size can be observed in the gel; the gel was cut and the target band was recovered using a gel recovery kit; the recovered target band was connected to the pCAGGS-X-myc vector after double digestion with EcoR I and Kpn I to construct a double mutant. The recovered target band was connected to the pCAGGS-X-myc vector after double digestion with EcoR I and Kpn I to construct a mutant pCAGGS-LASV GP / R207C-E329P-G360C, i.e., the LASV pre-fusion conformation GP plasmid pCAGGS-PF. The ligation reaction and subsequent transformation experiments were as described above. The PCR identification results of the pCAGGS-PF plasmid are as follows: Figure 6 As shown, a band consistent with the expected size can be observed, which preliminarily indicates that the plasmid was successfully constructed. The plasmid was sent to Shenggong Biotechnology Co., Ltd. for sequencing, which further indicated that the plasmid was successfully constructed and was stored for future use.

[0087] SEQ ID NO.8:

[0088] CATTATGTCCCTCAGGTGGTTCTTCATTATAAG;

[0089] SEQ ID NO.9:

[0090] GAAGAACCACCTGAGGGACATAATGTGCATCCCATACTGTAACTACA GCAAATACTGG.

[0091] 4. Construction of plasmid pCAGGS-PF-ND2 / N390D-N395D

[0092] On the basis of pCAGGS-PF, two glycosylation site mutations N390D and N395D were designed to construct a plasmid containing a prefusion conformation (PF) mutation site (R207C-E329P-G360C) and two glycosylation mutation sites (N390D-N395D). The LASV GP-PF-ND2 sequence was synthesized by Sangon Biotech (Shanghai) Co., Ltd. to obtain plasmid pUC-PF-ND2. The nucleotide sequence of LASV GP-PF-ND2 in the plasmid pUC-PF-ND2 is shown in SEQ ID NO.10. The plasmid pUC-PF-ND2 is obtained by inserting the sequence shown in SEQ ID NO.10 into the EcoR I and XhoI sites of pUC57.

[0093] SEQ ID NO.10:

[0094]

[0095] PCR was performed using pUC-PF-ND2 as a template, primer LASV GP-F-infu (gene sequence as shown in SEQ ID NO.2) as an upstream primer, and primer LASV GP-R-infu (gene sequence as shown in SEQ ID NO.3) as a downstream primer. The PCR products were subjected to 1% agarose gel electrophoresis ( Figure 7 ) and the gel was cut and recovered. The recovered target band was connected to the pCAGGS-X-myc vector after double digestion with EcoR I and Kpn I to construct the glycosylation site mutant plasmid pCAGGS-PF-ND2. The ligation reaction and subsequent transformation experiments were as described above; plasmid pCAGGS-PF-ND2 PCR was used as a template, and LASV GP-F-infu (gene sequence as shown in SEQ ID NO.2) and LASV GP-R-infu (gene sequence as shown in SEQ ID NO.3) were used as upstream and downstream primers for PCR identification, as shown in FIG. Figure 8 As shown, a band consistent with the expected size can be observed, which preliminarily indicates that the plasmid was successfully constructed. The plasmid was sent to Shenggong Biotechnology Co., Ltd. for sequencing, which further indicated that the plasmid was successfully constructed and was stored for future use.

[0096] 6. Construction of plasmid pCAGGS-PF-ND4 / N390D-N395D-N224D-N373D

[0097] On the basis of pCAGGS-PF-ND2, two glycosylation site mutations N224D and N373D were further designed to construct a plasmid containing a pre-fusion conformation (PF) mutation site R207C-E329P-G360C and four glycosylation mutation sites N390D-N395D-N224D-N373D. The LASV GP-PF-ND4 sequence was synthesized by Sangon Biotech (Shanghai) Co., Ltd. to obtain plasmid pUC-PF-ND4. The nucleotide sequence of LASV GP-PF-ND4 in the plasmid pUC-PF-ND4 is shown in SEQ ID NO.11. The plasmid pUC-PF-ND4 is obtained by inserting the sequence shown in SEQ ID NO.11 into EcoR I and XhoI of pUC57.

[0098] SEQ ID NO.11:

[0099]

[0100] After double restriction digestion of pUC-PF-ND4, the target band LASV GP-PF-ND4 was electrophoresed by 1% agarose gel electrophoresis ( Fig. 9 ) and the gel was cut and recovered. The recovered target band was ligated with the pCAGGS-X-myc vector after double digestion with EcoR I and Kpn I to construct the glycosylation site four-mutant plasmid pCAGGS-PF-ND4 / N390D-N395D-N224D-N373D. The ligation reaction and subsequent transformation experiments were as described above. The double digestion identification results of the pCAGGS-PF-ND4 (N390D-N395D-N224D-N373D) plasmid were as follows: Fig.10 As shown, a band consistent with the expected size can be observed, which preliminarily indicates that the plasmid was successfully constructed. The plasmid was sent to Shenggong Biotechnology Co., Ltd. for sequencing, which further indicated that the plasmid was successfully constructed and was stored for future use.

[0101] 7. Construction of plasmid pCAGGS-PF-ND4-R4 / N390D-N395D-N224D-N373D-RRRR

[0102] On the basis of the mutation site of pCAGGS-PF-ND4, the restriction site mutation was further designed to construct a plasmid containing a pre-fusion conformation (PF) mutation site (R207C / E329P / G360C), four glycosylation mutation sites (N390D / N395D / N224D / N373D) and a restriction site mutation (L258R / L259R). SKI-1 / S1P protease is a protease in cells that can recognize the amino acid sequence RRLL at positions 256, 257, 258 and 259 on LASV GP. In the present invention, after the amino acids LL at positions 258 and 259 are mutated to RR, the SKI-1 / S1P protease will not be able to recognize the sequence and will not be able to cut the LASV GP protein precursor, thereby forming a full-length non-cut LASV GPC. The LASV GP-PF-ND4-R4 sequence was synthesized by Sangon Biotechnology (Shanghai) Co., Ltd. to obtain plasmid pUC-PF-ND4-R4. The nucleotide sequence of LASV GP-PF-ND4-R4 in the plasmid pUC-PF-ND4-R4 is as follows. The plasmid pUC-PF-ND4 is obtained by inserting the sequence shown in SEQ ID NO.12 into the EcoR I and XhoI sites of the pUC57 vector.

[0103] SEQ ID NO.12:

[0104] ATGGGACAAATTGTGACCTTCTTCCAGGAGGTGCCTCATGTGATTGAGGAGGTGATGAACATTGTGCTGATTGCCCTGTCTGTGCTGGCTGTGCTGAAAGGACTCTACAACTTTGCCACTTGTGGACTGGTGGGACTGGTGACCTTCCTGCTGCTGTGTGGCAGGTCCTGTACCACCTCCCTCTACAAGGGAGTCTATGAACTCCAAACCTTGGAACTGAATATGGAGACCCTGAATATGACAATGCCACTGTCCTGTACCAAGAACAACAGCCACCACTACATAATGGTGGGCAATGAGACAGGATTGGAACTGACCCTGACCAACACCAGCATCATCAACCACAAGTTCTGTAACCTGTCTGATGCCCACAAGAAGAACCTCTATGACCATGCCCTGATGAGTATCATCAGCACCTTCCACCTGAGCATCCCAAACTTCAACCAATATGAGGCTATGAGTTGTGACTTCAATGGAGGCAAGATTTCTGTCCAATACAACCTGAGCCACTCCTATGCTGGAGATGCTGCCAACCACTGTGGCACAGTGGCTAATGGAGTGCTCCAAACCTTTATGAGGATGGCTTGGGGAGGCTCCTACATTGCCCTGGACTCTGGCtGcGGCAACTGGGACTGTATAATGACCTCCTACCAATACCTGATTATCCAGgACACCACCTGGGAGGACCACTGTCAGTTCAGCAGACCAAGCCCAATTGGCTACCTGGGACTGCTGAGCCAGAGGACCAGGGACATCTACATCAGCAGGAGAAGGAGAGGCACCTTCACCTGGACCCTGTCTGACTCTGAGGGCAAGGACACACCTGGAGGCTACTGTCTGACCAGG.

[0105] After double restriction digestion of pUC-PF-ND4-R4, the target band LASVGP-PF-ND4-R4 was subjected to 1% agarose gel electrophoresis ( Fig. 9 ) and the gel was cut and recovered. The recovered target band was ligated with the pCAGGS-X-myc vector after double digestion with EcoR I and Kpn I to construct the plasmid pCAGGS-PF-ND4-R4 (N390D\N395D\N224D\N373D\RRRR) with four mutations in glycosylation sites. The ligation reaction and subsequent transformation experiments were as described above. The results of double digestion of the pCAGGS-PF-ND4-R4 (N390D\N395D\N224D\N373D\RRRR) plasmid were as follows: Fig.10 As shown, a band consistent with the expected size can be observed, which preliminarily indicates that the plasmid was successfully constructed. The plasmid was sent to Shenggong Biotechnology Co., Ltd. for sequencing, which further indicated that the plasmid was successfully constructed and was stored for future use.

[0106] 2. Plasmid construction based on pVAX1 vector

[0107] Using the successfully constructed plasmids pCAGGS-PF, pCAGGS-PF-ND2, pCAGGS-PF-ND4 and pCAGGS-PF-ND4-R4 as templates, relevant upstream and downstream primers were designed, including the LASV-GP-R-infu pVAX Xho I primer with a gene sequence as shown in SEQ ID NO.13 and the LASV-GP-F-infupVAX EcoR I primer with a gene sequence as shown in SEQ ID NO.14, and LASV GP-PF, LASV GP-PF-ND2, LASV GP-PF-ND4 and LASVGP-PF-ND4-R4 fragments were amplified by PCR. The specific PCR reaction system and reaction conditions refer to the above method.

[0108] The PCR products were electrophoresed on 1% agarose gel ( Fig.11 , Fig.12 ) and the gel was cut and recovered. The recovered target band was ligated with the pVAX1 vector after double digestion with EcoR I and Xho I to construct plasmids pVAX1-PF, pVAX1-PF-ND, pVAX1-PF-ND4 and pVAX1-PF-ND4-R4. The ligation reaction and subsequent transformation experiments were as described above.

[0109] The successfully constructed plasmid was then identified by PCR using the LASV-GP-R-infu primer shown in SEQ ID NO.2 and the LASV-GP-F-infu primer shown in SEQ ID NO.3. Fig.13 As shown, a band consistent with the expected size can be observed, which preliminarily indicates that the plasmid was successfully constructed. The plasmid was sent to Shenggong Biotechnology Co., Ltd. for sequencing, which further indicated that the plasmid was successfully constructed and was stored for future use.

[0110] SEQ ID NO.13

[0111] CGGGCCCTCTAGACTCGAGTCATTACAGGTCCTCCTCTGAGATCAGC TTC;

[0112] SEQ ID NO.14

[0113] GTCCAGTGTGGTGGAATTCGCCACCATGGGACAAATTGTGACCTTCT TCCAGGAG.

[0114] 3. Western Blot (WB) Identification of Pre-fusion Conformation and Glycosylation Site Mutations

[0115] BHK cells were inoculated in two six-well plates and cultured overnight until the cell density was about 70%. 4 μg of pVAX1 vector plasmid, pVAX1-GP plasmid, pVAX1-PF plasmid, pVAX1-PF-ND2 plasmid, pVAX1-PF-ND4 plasmid and pVAX1-PF-ND4-R4 plasmid were transfected respectively, among which pVAX1 was a negative control and pVAX1-GP was a positive control. After 24 hours, the DMEM medium in the six-well plate was discarded, and the plate was washed twice with PBS. 100 μL of RIPA lysis buffer (containing protease inhibitors) was added to each well, and the cells were lysed on ice for 30 minutes. The cells were scraped and placed in a 1.5 mL EP tube, centrifuged at 12000×g for 15 minutes, and the supernatant was transferred to a new 1.5 mL In the EP tube, after BCA quantification, add the corresponding SDS-PAGE protein loading buffer (5×), heat the sample at 100℃ or in a boiling water bath for 3-5min, and then cool to room temperature, directly load it into the SDS-PAGE gel loading hole for electrophoresis and transfer to PVDF membrane, dilute the primary antibody according to the antibody instructions and add it to the PVDF membrane, incubate it on a shaker at 4℃ overnight, wash it on a shaker with TBST 3 times, 10min each time; dilute the secondary antibody with TBST (1:5000) and add it to the membrane, incubate it at room temperature for 1h, wash it on a shaker with TBST 3 times, 10min each time, use enhanced chemiluminescence to develop the color, put the PVDF membrane into the Tianneng chemiluminescence instrument, lay it with the front side facing up, add the luminescence working solution to the membrane in a 1:1 ratio (different amounts according to needs), pay attention to avoid light, and then operate the instrument to expose and take pictures.

[0116] The experimental results are as follows Fig.14 As shown, the positive controls pVAX1-GP, pVAX1-PF, pVAX1-PF-ND2, pVAX1-PF-ND4 and pVAX1-PF-ND4-R4 all had specific bands around 70 kD; unlike the positive control pVAX1-GP, no specific bands were detected around 35 kD for pVAX1-PF, pVAX1-PF-ND2, pVAX1-PF-ND4 and pVAX1-PF-ND4-R4, indicating that pVAX1- After the introduction of disulfide bond and proline mutations, no conformational changes occurred in PF, pVAX1-PF-ND2, pVAX1-PF-ND4 and pVAX1-PF-ND4-R4. The two subunits GP1 and GP2 were not separated, and the pre-fusion conformation was maintained. At the same time, the band sizes of pVAX1-PF-ND2, pVAX1-PF-ND4 and pVAX1-PF-ND4-R4 were slightly smaller than those of pVAX1-GP and pVAX1-PF, indicating that the glycosylation site mutations were successfully introduced.

[0117] IV. Experimental Animal Grouping and Immunization Strategy

[0118] The pVAX1 vector (EV group), pVAX1-PF plasmid, pVAX1-PF-ND2 plasmid, pVAX1-PF-ND4 plasmid and pVAX1-PF-ND4-R4 plasmid were injected into the bilateral muscles of the thigh roots of the hind limbs of BALB / c mice at a dose of 70 μg per mouse.

[0119] The immunization process consisted of two injections, 4 weeks apart. Two weeks after the last immunization, the mice were anesthetized and killed to collect blood and dissect the spleen to measure the cellular immune response indexes and humoral immune response indexes.

[0120] 5. Detection of cellular immune indicators in experimental animals

[0121] 1. Preparation of Mouse Spleen Single Cell Suspension

[0122] 1) After blood was collected from the eyeball, the mice were killed and soaked in 75% ethanol for 5 min. The mice were then fixed in a clean bench;

[0123] 2) Take the mouse spleen and place it in a sterile 10 cm culture dish, add PBS to rinse and remove excess connective tissue, cut the spleen into small pieces of 3-4 mm with scissors, put it into a 70 μm mesh, and grind it with the piston shaft of a 10 mL syringe. While grinding, add RPMI-1640 culture medium containing 2% FBS dropwise until the spleen cells are filtered out;

[0124] 3) Transfer the spleen cells to a 15 mL centrifuge tube, remove the supernatant by centrifugation, add 3 mL of red blood cell lysis buffer to resuspend, and place on ice for 15 minutes, gently inverting and mixing twice during the process (after red blood cell lysis, spleen cells are white);

[0125] 4) Centrifuge for 10 min, discard the supernatant, continue to add PBS to stop digestion and washing, the precipitate is the mouse spleen cells, resuspend the cells in RPMI-1640 complete medium, count and adjust the cell concentration to 4×10 6 / mL;

[0126] 2.ELISpot detection of cytokine secretion levels of mouse spleen cells

[0127] 1) The secretion levels of IFN-γ, IL-2, IL-4 and IL-10 cytokines in the spleen cells of mice in each immunization group were detected using ELISpot kit.

[0128] 2) Wash the ELISpot plate three times with sterile PBS, and then add blocking solution and block at room temperature for 2 hours.

[0129] 3) Discard the blocking solution in the plate and plate mouse spleen cells at a rate of 2×10 6Each well was added to the ELISpot plate, and the LASV GP peptide pool (peptide designed according to the amino acid sequence of the IV series LASV structural protein) was added to each experimental well. An equal amount of Concanavalin A (Con A) was added to the positive control well as a stimulator. At the same time, negative control wells (no stimulator was added) and background control wells (the wells only contained cell culture medium) were set up.

[0130] 4) Place the ELISpot plate in a 37°C, CO2 cell culture incubator for 24 hours. Discard the cells, wash three times with PBST, add diluted biotin-labeled IFN-γ / IL-2 / IL-4 / IL-10 antibodies, and incubate at room temperature for 1 hour.

[0131] 5) After washing three times with PBST, add diluted HRP-labeled anti-biotin antibody and incubate at room temperature for 1 hour.

[0132] 6) After washing with PBST for 3 times, add TMB substrate colorimetric solution. Observe the bottom of the well plate. After the spots are formed, wash the ELISpot plate with deionized water to terminate the colorimetric reaction.

[0133] 7) After the ELISpot plate is dried, use an ELISpot scanner to detect and calculate the number of spot-forming cells (SFC).

[0134] The experimental results are as follows Fig.15 As shown in Figures 16, 17, and 18, when mouse spleen cells were stimulated by LASV GP, the secretion levels of specific IFN-γ, IL-2, IL-4, and IL-10 induced by the PF-ND4 and PF-ND4-R4 groups were significantly higher than those of the PF and EV groups.

[0135] 6. Detection of humoral immunity indicators of experimental animals

[0136] 1. Collecting Mouse Serum

[0137] After the mouse is anesthetized, fix the animal and take out the tail. Soak the tail in 45℃ warm water for several minutes to make the tail blood vessels engorged and dilated. Wipe the tail dry, disinfect the tail with alcohol cotton balls, quickly cut off the tail tip about 1-2mm with scissors, massage the mouse tail from the tail root to the tail tip to let the blood flow out, and collect the blood with a blood collection tube. After blood collection, use cotton balls to press and stop bleeding. After obtaining blood by the above method, let it stand at room temperature for more than 1 hour in an EP tube, centrifuge it at 3000×g for 10 minutes, and the supernatant is serum, which is stored in a -80℃ refrigerator.

[0138] 2. Detection of LASV neutralizing antibodies in mouse serum

[0139] HEK-293T cells were plated in 6-well plates and transfected with plasmid pCMV3-LASVGP at 4 μg / well until the cell density reached 80%. After 24 hours, the culture medium was discarded and the cells were transfected with 1000 TCID 50 / well was infected with pVSV-dG.G-Nluc. After infection at 37℃ for 2h, the virus solution was discarded, the cells were washed 3 times with 1×PBS, 2% DMEM was added at 1mL / well and continued to incubate. After 24h, the supernatant was collected into a 15mL centrifuge tube and centrifuged at 2000rpm for 5min. The supernatant was pVSV-LASV-Nluc, which could be used for the detection of LASV neutralizing antibodies after titration.

[0140] After immunization, the mouse sera were diluted to 100 μL in a 96-well plate at 1:20, 1:40, 1:80, 1:160, 1:320, 1:640, and 1:1280, respectively, and mixed with an equal volume of 650 TCID 50 pVSV-LASV-Nluc were mixed; incubated at 37°C for 1 h to allow the virus to fully contact the serum. Two replicate wells were set for each dilution, and pVSV-LASV-Nluc infection wells were also set; VeroE6 cells were digested and counted at 2.5×10 5 / well of a 96-well plate and incubated at 37°C to allow the unneutralized virus to infect VeroE6 cells. After 24 hours, the supernatant was discarded, and the cells were washed 3 times with 1×PBS. 1×PLB was added at 50μL / well to lyse the cells at room temperature. After 15 minutes, 10μL of the lysate was pipetted into a white 96-well plate (opaque bottom) per well, and an equal volume of luciferase substrate was added. The fluorescence signal unit (Relative light unit, RLU) was detected in an ELISA instrument, and the neutralization efficiency of the mouse serum in each group was calculated according to the following formula, (RLU Control -RLU Serum ) / RLU Control .

[0141] The neutralizing antibody activity of the serum of each group of mice was detected by a pseudovirus neutralization test based on pVSV-LASV-Nluc. Fig.19 As shown, the neutralization efficiency of sera in the PF-ND4-R4 group and the PF-ND4 group was higher than that in the EV group, the PF group and the PF-ND2 group, indicating that based on the pre-fusion conformation (PF) of LASV GP, glycosylation mutations at four sites and glycosylation mutations combined with enzyme cleavage site mutations can induce the production of high-level neutralizing antibodies.

[0142] SEQ ID NO.15:

[0143] ATGGTCTCACACTCGAAGATTTCGTTGGGGACTGGCGACAGACAGCCGGCTACAACCTGGACCAAGTCCTTGAACAGGGAGGTGTGTCCAGTTTGTTTCAGAATCTCGGGGTGTCCGTAACTCCGATC CAAAGGATTGTCCTGAGCGGTGAAAATGGGCTGAAGATCGACATCCATGTCATCATCCCGTATGAAGGTCTGAGCGGCGACCAAATGGGCCAGATCGAAAAAATTTTTAAGGTGGTGTACCCTGTGGAT GATCATCACTTTAAGGTGATCCTGCACTATGGCACACTGGTAATCGACGGGGTTACGCCGAACATGATCGACTATTTCGGACGGCCGTATGAAGGCATCGCCGTGTTCGACGGCAAAAAGATCACTGTA ACAGGGACCCTGTGGAACGGCAACAAAATTATCGACGAGCGCCTGATCAACCCCGACGGCTCCCTGCTGTTCCGAGTAACCATCAACGGAGTGACCGGCTGGCGGCTGTGCGAACGCATTCTGGCGTAA.

[0144] SEQ ID NO.16:

[0145] GAGCAGAAGCTGATCTCAGAGGAGGACCTG.

[0146] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0147] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A LASV GP protein mutant, characterized in that: The LASV GP protein mutant is obtained by performing amino acid mutation modification on the wild-type LASV GP full-length sequence as shown in SEQ ID NO.

1. The LASV GP protein mutant is obtained by any one of the following two methods: (1) The arginine R at position 207 of SEQ ID NO.1 was mutated to cysteine ​​C, the glutamic acid E at position 329 was mutated to proline P, the glycine G at position 360 was mutated to cysteine ​​C, and the asparagine N at positions 390, 395, 224 and 373 were mutated to aspartic acid D; (2) The arginine R at position 207 of SEQ ID NO.1 is mutated to cysteine ​​C, the glutamic acid E at position 329 is mutated to proline P, the glycine G at position 360 is mutated to cysteine ​​C, the asparagine N at positions 390, 395, 224 and 373 are mutated to aspartic acid D, and the leucine L at positions 258 and 259 are mutated to arginine R.

2. The LASV GP protein mutant according to claim 1, characterized in that: The coding gene sequence of the LASVGP protein mutant obtained by the method described in (1) is shown in SEQ ID NO.

11.

3. The LASV GP protein mutant according to claim 1, characterized in that: The coding gene sequence of the LASVGP protein mutant obtained by the method described in (2) is shown in SEQ ID NO.

12.

4. A biomaterial, characterized in that: At least one of the following (1)-(4): (1) A nucleic acid molecule encoding the LASV GP protein mutant according to claim 1; (2) a recombinant vector containing the nucleic acid molecule described in (1); (3) a recombinant microorganism containing the nucleic acid molecule described in (1) or a recombinant microorganism containing the recombinant vector described in (2); (4) A recombinant cell line containing the nucleic acid molecule described in (1) or a recombinant cell line containing the recombinant vector described in (2).

5. Use of the LASV GP protein mutant according to claim 1 or the biomaterial according to claim 5 in any one of the following (1)-(3): (1) Preparing anti-LASV products; (2) preparing products for the prevention and / or treatment of LASV infection; (3) Preparation of products for preventing and / or treating diseases caused by LASV.

6. A neutralizing antibody-inducing LASV vaccine, characterized in that: The active ingredient is the LASV GP protein mutant described in claim 1 or the biological material described in claim 4.

7. The vaccine according to claim 5, characterized in that The vaccine is a DNA vaccine, an mRNA vaccine, a recombinant protein subunit vaccine, a recombinant protein subunit vaccine displayed by nanoparticles, or a recombinant vector vaccine.

8. The vaccine according to claim 7, characterized in that The vaccine is in the form of an aqueous solution or a lyophilized preparation.

9. Use of the vaccine according to claim 8 in any one of the following (1)-(3): (1) Preparing anti-LASV products; (2) preparing products for the prevention and / or treatment of LASV infection; (3) Preparation of products for preventing and / or treating diseases caused by LASV.

Citation Information

Cited By

  • Lassa virus GPC protein pre-fusion conformation mutant and application thereof

    CN119552226A

  • Lassa virus mRNA vaccine with prefusion conformation GPC as target and preparation method thereof

    CN120695172A